Fecal microbiota transplants and freeze-dried stool capsules are expanding beyond treating recurrent infections, with new research showing promise in reducing immunotherapy side effects for cancer patients and improving sleep efficiency in individuals with chronic insomnia, alongside ongoing standardization efforts by federal scientists.
Human waste is finding a rigorous new role in modern medicine. While fecal microbiota transplants have long been used to treat stubborn bacterial infections, laboratories and clinical researchers are now investigating whether donor microbes can reshape treatments for cancer, chronic sleep disorders, and other complex health conditions.
Federal Standardization of Microbial Reference Materials
To support this growing field, government researchers are establishing baseline standards for studying gut bacteria.
Between 30% and 50% of human stool consists of bacteria, viruses, fungi, and other microorganisms that inhabit the gut, playing vital roles in metabolism, digestion, and immune regulation. Because direct gut sampling requires invasive procedures like colonoscopies or biopsies, stool collection offers a convenient alternative for analyzing microbiome health. Researchers note that microbial DNA sequencing from stool samples could eventually help evaluate disease risks much like human genetic testing.
“This isn’t just wishful thinking. It’s already happening,” said NIST molecular geneticist Scott Jackson. “We are at the beginning of a new era of medicine.”
Scott Jackson, NIST molecular geneticist
The therapeutic use of fecal transplants is already established for recurrent Clostridioides difficile infection, a dangerous bacterial condition frequently contracted in hospitals. According to federal reporting, the procedure achieves a 95% success rate in clearing recurrent CDI by helping regenerate a healthy gut ecosystem.
Canadian Clinical Trials Target Cancer Therapy Side Effects
Recent clinical trials in Canada indicate that oral fecal microbiota transplant capsules, commonly referred to as poop pills, may reduce the severe side effects of cancer medications while supporting patient response to immunotherapy. Researchers evaluated freeze-dried fecal matter capsules produced by the Lawson Research Institute in London, Ontario.
In the first phase of the research, scientists at the London Health Sciences Centre Research Institute and the Lawson Research Institute analyzed data from 20 patients to test the safety of combining fecal microbiota transplants with kidney cancer immunotherapy.
“Standard treatment for advanced kidney cancer often includes an immunotherapy drug that helps the patient’s immune system tackle cancer cells. But, unfortunately, the treatment frequently leads to colitis and diarrhea, sometimes so severe that a patient must stop life-sustaining treatment early. If we can reduce toxic side effects and help patients complete their treatment, that will be a game-changer.”
Saman Maleki, scientist at LHSCRI
A second phase led by researchers at the Centre de recherche du Centre hospitalier de l’Université de Montréal evaluated patients with lung cancer and melanoma. Investigators found that 80% of lung cancer patients responded to immunotherapy after the transplant, compared with 39% to 45% of patients treated with immunotherapy alone. Among melanoma patients, 75% responded positively following the transplant, compared with 50% to 58% in the control group.
“Our clinical trial demonstrated that fecal microbiota transplantation could improve the efficacy of immunotherapy in patients with lung cancer and melanoma,” said Dr. Arielle Elkrief, co-principal investigator and a physician scientist at CRCHUM.
Dr. Arielle Elkrief, co-principal investigator and physician scientist at CRCHUM
Investigating Gut Microbes as a Potential Aid for Insomnia
Beyond oncology, early clinical investigations are examining whether reprogramming the gut microbiome can alleviate chronic sleep disorders. A small study published in the Journal of Internal Medicine and highlighted by livescience.com followed 80 adult men and women with long-term insomnia across seven hospitals in China.
In the trial, half of the participants took antibiotics for two days to clear existing gut bacteria before swallowing 60 capsules containing microbial isolates from healthy donors confirmed to be good sleepers, followed by a booster dose of 20 capsules two weeks later. The control group received placebo pills.
Using overnight polysomnography assessments, researchers found that sleep efficiency in the treatment group jumped from 79% to 93% one month after the procedure, whereas the placebo group shifted only slightly from 85% to 87%. Treated participants also experienced less nighttime wakefulness, with post-sleep awake time dropping from 79 to 17 minutes. Side effects were reported as mild and occurred in only three of the 40 treated participants.
Independent specialists noted that while the findings are encouraging, the trial was small and limited to relatively healthy adults. Experts emphasized that the results should be viewed as preliminary proof-of-concept evidence rather than an established clinical treatment for sleep disorders, leaving researchers to continue exploring how gut-brain communication pathways influence neurological and metabolic health.
